(Q46189130)

20 December 2017

title

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma (English)

1 reference

20 December 2017

2

Eric J Small

1 reference

20 December 2017

author name string

Andrea L Harzstark

1

1 reference

20 December 2017

Vivian K Weinberg

3

1 reference

20 December 2017

Janine Sun

4

1 reference

20 December 2017

Charles J Ryan

5

1 reference

20 December 2017

Amy M Lin

6

1 reference

20 December 2017

Lawrence Fong

7

1 reference

20 December 2017

Dion R Brocks

8

1 reference

20 December 2017

Jonathan E Rosenberg

9

1 reference

20 December 2017

language of work or name

English

0 references

publication date

8 March 2011

1 reference

20 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

20 December 2017

volume

117

1 reference

20 December 2017

issue

18

1 reference

20 December 2017

page(s)

4194-4200

1 reference

20 December 2017

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25931

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25931

1 reference

20 December 2017

1 reference

20 December 2017